Oxford BioDynamics PLC - Oxford, England-based biotechnology company has two blood testing products on market, the PSE prostate cancer screening test and the CiRT checkpoint inhibitor response test - Raises £350,000 via retail share offer at 0.5 pence per share. This is in addition to £7.0 million raised by placing and subscription at the same price, announced on Wednesday.
Proceeds will provide additional working capital and cash runway to support the continued commercial development of the EpiSwitch product line.
Oxford BioDynamics is currently undertaking a strategic review. Expects this to result in a greater focus on establishing partnerships, collaborations and licensing deals as a way of accelerating sales. As a result of this, company anticipates there will be a need to re-structure the business.
Current stock price: 0.60 pence, closed down 4.4% in London on Friday
12-month change: down 98%
Copyright 2025 Alliance News Ltd. All Rights Reserved.
